Cambridge Innovation Capital

Phosphor AI is an AI-driven educational technology company based in Cambridge, UK, with significant operations in Hong Kong. It specializes in creating personalized AI tutoring solutions for secondary education, preparing students for major exams like A Level, IB, AP, IGCSE, DSE, and SAT. The platform leverages advanced AI to provide affordable, dynamic, and tailored learning experiences. Supported by significant investments from Chinese VC, incubation by HKSTP, and resources from Microsoft, Phosphor AI focuses on democratizing education and fostering global talent. It collaborates with Cambridge University entities and Singaporean VCs to support AI and engineering research, aiming to commercialize patents and advance technological innovation.

Pragmatic specializes in ultra-low-cost flexible electronics. Its FlexICs, thinner than human hair, enable innovative solutions by embedding circuits invisibly into objects. The company offers a FlexIC Foundry service for custom application-specific devices and standard FlexIC products for mass market use cases like RFID and NFC. Pragmatic's revolutionary FlexLogIC production system facilitates high-volume manufacturing at significantly lower costs compared to traditional silicon IC fabs. Headquartered in Cambridge, UK, with a billion-unit production facility in Sedgefield, the company serves diverse markets such as consumer goods, retail, healthcare, and gaming.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

PetMedix Ltd is a veterinary biopharmaceutical company based in Hinxton, United Kingdom, that specializes in therapeutic drug discovery for pets. Founded in 2017, the company utilizes advanced scientific techniques to develop innovative antibody therapies aimed at improving the health and well-being of companion animals. PetMedix has created specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce therapeutic-quality antibodies tailored for pets. This approach allows for the generation of a diverse repertoire of antibodies that mirrors the immune systems of companion animals, enabling veterinarians to administer safe and effective monoclonal antibody treatments. By applying over thirty years of expertise in human drug development to veterinary medicine, PetMedix is dedicated to enhancing the quality of life for pets through cutting-edge therapies.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, utilizes advanced molecular methods, including polymerase chain reaction (PCR), to deliver rapid and accurate results. This capability allows clinics and medical professionals to detect infections swiftly and make informed treatment decisions in a decentralized healthcare setting, ultimately improving patient outcomes.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

AudioTelligence Ltd is a company based in Cambridge, United Kingdom, specializing in advanced audio processing technology. Founded in 2017, AudioTelligence focuses on developing software that enhances the clarity and intelligibility of audio captured from multiple microphones, addressing the challenges posed by loud background noise in conversations. The company employs a data-driven technique known as blind audio signal separation, which significantly outperforms traditional methods such as beamforming and deep neural networks. This innovative technology aims to improve automatic speech recognition (ASR) systems, enabling businesses to provide clearer and more understandable speech for both users and voice-activated devices.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, utilizes advanced molecular methods, including polymerase chain reaction (PCR), to deliver rapid and accurate results. This capability allows clinics and medical professionals to detect infections swiftly and make informed treatment decisions in a decentralized healthcare setting, ultimately improving patient outcomes.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

PolyProx Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2018. It focuses on researching and developing innovative drug therapies aimed at treating cancer and neurodegenerative diseases. The company's flagship product, Polyproxin, utilizes engineered proteins that selectively target tumor cells. This mechanism activates the natural degradation processes within the cells, allowing for the removal of disease-causing proteins. By employing this novel approach, PolyProx aims to provide effective treatment options for cancer patients, potentially improving their outcomes and quality of life.

Cytora provides a configurable risk digitization and analytics platform for commercial insurance. The platform digitizes each incoming risk, augments it with internal and external data sources, and evaluates it against rules governing appetite and priority before routing to downstream underwriting systems for automated or manual processing. Using artificial intelligence, Cytora learns patterns of risk and loss outcomes over time, computes a risk rank, score, and price for each property and organization, and helps insurers target profitable risks, improve risk selection, and optimize pricing. The company was founded in 2014 and is headquartered in London.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Pragmatic specializes in ultra-low-cost flexible electronics. Its FlexICs, thinner than human hair, enable innovative solutions by embedding circuits invisibly into objects. The company offers a FlexIC Foundry service for custom application-specific devices and standard FlexIC products for mass market use cases like RFID and NFC. Pragmatic's revolutionary FlexLogIC production system facilitates high-volume manufacturing at significantly lower costs compared to traditional silicon IC fabs. Headquartered in Cambridge, UK, with a billion-unit production facility in Sedgefield, the company serves diverse markets such as consumer goods, retail, healthcare, and gaming.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.

Founded in 2015 and headquartered in Cambridge, UK, Morphogen-IX is a biotechnology company focused on developing novel therapies for pulmonary arterial hypertension (PAH). The company's core expertise lies in bone morphogenetic proteins (BMPs), with a particular emphasis on BMP9 and BMP10. Its semi-virtual model combines an experienced team of drug discovery professionals with outsourced development programs, aiming to maximize capital efficiency while maintaining high-quality research.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

CEDAR Audio is a Cambridge, UK-based company focused on audio restoration and speech enhancement for film, post-production, television and radio broadcasting, CD and DVD mastering, libraries and archives, and audio forensic investigations. Established in 1988 following five years of research funded by the British Library National Sound Archive, it maintains strong academic links with Cambridge University and counts two Cambridge University professors and a director of studies among its directors. The company develops and manufactures hardware-based restoration systems and pursues ongoing research into new techniques in audio restoration and speech enhancement, while prioritizing high-quality customer support and industry recognition.

AudioTelligence Ltd is a company based in Cambridge, United Kingdom, specializing in advanced audio processing technology. Founded in 2017, AudioTelligence focuses on developing software that enhances the clarity and intelligibility of audio captured from multiple microphones, addressing the challenges posed by loud background noise in conversations. The company employs a data-driven technique known as blind audio signal separation, which significantly outperforms traditional methods such as beamforming and deep neural networks. This innovative technology aims to improve automatic speech recognition (ASR) systems, enabling businesses to provide clearer and more understandable speech for both users and voice-activated devices.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Undo Ltd., established in 2005, specializes in developing debugging tools for software developers. Its flagship product, LiveRecorder, records and replays software execution to aid in identifying and fixing programming errors. UndoDB, another key offering, provides an interactive reversible debugger for C/C++ on Linux and Android platforms. The company serves industries such as data management, networking, electronic design automation, and finance, with offices in Cambridge, UK, and San Francisco, CA.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Cytora provides a configurable risk digitization and analytics platform for commercial insurance. The platform digitizes each incoming risk, augments it with internal and external data sources, and evaluates it against rules governing appetite and priority before routing to downstream underwriting systems for automated or manual processing. Using artificial intelligence, Cytora learns patterns of risk and loss outcomes over time, computes a risk rank, score, and price for each property and organization, and helps insurers target profitable risks, improve risk selection, and optimize pricing. The company was founded in 2014 and is headquartered in London.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

Z Factor Limited is a drug discovery company established in 2015 with a focus on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company is dedicated to designing innovative treatments that address the misfolding of the Z variant of alpha-1-antitrypsin. This condition presents significant medical challenges, and current treatment options are largely restricted to lung or liver transplantation and augmentation therapy. By targeting the underlying causes of the disease, Z Factor aims to fulfill a critical unmet medical need in the field of respiratory and liver health.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.

Undo Ltd., established in 2005, specializes in developing debugging tools for software developers. Its flagship product, LiveRecorder, records and replays software execution to aid in identifying and fixing programming errors. UndoDB, another key offering, provides an interactive reversible debugger for C/C++ on Linux and Android platforms. The company serves industries such as data management, networking, electronic design automation, and finance, with offices in Cambridge, UK, and San Francisco, CA.

Pragmatic specializes in ultra-low-cost flexible electronics. Its FlexICs, thinner than human hair, enable innovative solutions by embedding circuits invisibly into objects. The company offers a FlexIC Foundry service for custom application-specific devices and standard FlexIC products for mass market use cases like RFID and NFC. Pragmatic's revolutionary FlexLogIC production system facilitates high-volume manufacturing at significantly lower costs compared to traditional silicon IC fabs. Headquartered in Cambridge, UK, with a billion-unit production facility in Sedgefield, the company serves diverse markets such as consumer goods, retail, healthcare, and gaming.

Fluidic Analytics Limited, founded in 2013 as a spin-out from the University of Cambridge, specializes in the design, development, and manufacturing of advanced analytical tools for protein characterization. The company focuses on creating innovative products that facilitate in-solution sizing and quantification of proteins, with offerings such as Fluidity One and Fluidity One-W, which enable high sensitivity analysis of protein size and interaction kinetics. These tools are essential for a variety of applications, including assessing protein quality, interactions, and aggregation. Fluidic Analytics serves a diverse clientele, including scientists, clinics, and healthcare providers, aiming to enhance the understanding of protein behavior and its implications in biological processes. By combining cutting-edge technology with a commitment to accessibility and user data ownership, the company aspires to transform the field of protein science, paralleling the revolutionary impact of advancements in DNA sequencing.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Founded in 2015 and headquartered in Cambridge, UK, Morphogen-IX is a biotechnology company focused on developing novel therapies for pulmonary arterial hypertension (PAH). The company's core expertise lies in bone morphogenetic proteins (BMPs), with a particular emphasis on BMP9 and BMP10. Its semi-virtual model combines an experienced team of drug discovery professionals with outsourced development programs, aiming to maximize capital efficiency while maintaining high-quality research.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.

Abcodia is a biotechnology company specializing in the discovery and validation of molecular biomarkers for disease diagnosis and screening, with a particular focus on cancer. Founded in 2010 and headquartered in Cambridge, UK, Abcodia utilizes its unique longitudinal serum biobank and collaborations with academic institutions like UCL, technology platform providers, and leading diagnostic companies to support the entire diagnostic development process. The company offers Roca Test solutions for early ovarian cancer detection, serving customers across multiple states in the US and the United Kingdom.

Undo Ltd., established in 2005, specializes in developing debugging tools for software developers. Its flagship product, LiveRecorder, records and replays software execution to aid in identifying and fixing programming errors. UndoDB, another key offering, provides an interactive reversible debugger for C/C++ on Linux and Android platforms. The company serves industries such as data management, networking, electronic design automation, and finance, with offices in Cambridge, UK, and San Francisco, CA.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Pragmatic specializes in ultra-low-cost flexible electronics. Its FlexICs, thinner than human hair, enable innovative solutions by embedding circuits invisibly into objects. The company offers a FlexIC Foundry service for custom application-specific devices and standard FlexIC products for mass market use cases like RFID and NFC. Pragmatic's revolutionary FlexLogIC production system facilitates high-volume manufacturing at significantly lower costs compared to traditional silicon IC fabs. Headquartered in Cambridge, UK, with a billion-unit production facility in Sedgefield, the company serves diverse markets such as consumer goods, retail, healthcare, and gaming.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.